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mammalian hosts (9). Drug resistance
or sensitivity is based on sequences of
M2 and NA. Substitution within
residues including L26I, V27A/I,
A30S, and S31N of the M2 ion chan-
nel protein was used to predict aman-
tadine-resistant mutants, and H274Y
of the NA was used to predict for
oseltamivir resistance (10). The virus
observed in 2006 isolates from Phi-
chit was resistant to amantadine but
sensitive to oseltamivir, whereas the
isolate from Nakhon Phanom was
sensitive to amantadine and
oseltamivir, which implies that infect-
ed patients received different antiviral
drugs.
According to previous World
Health Organization reports, the HA
sequences of most influenza (H5N1)
viruses that circulated in avian species
during the past 3 years are separated
into 2 distinct phylogenetic clades.
Clade 1 viruses that circulated in
Cambodia, Thailand, and Vietnam
were responsible for human infections
in those countries during 2004 and
2005. Clade 2 viruses that circulated
in birds in People’s Republic of China
and Indonesia during 2003–2004 and
2005–2006 spread westward to the
Middle East, Europe, and Africa. This
latter genetic group of viruses has
been principally responsible for
human infections during late 2005
and 2006 (11). The latest wave of the
outbreaks in Thailand was caused by
viruses closely related to those that
caused outbreaks in Thailand in
2004–2005 and to viruses recently
circulating in southeast People’s
Republic of China and other South-
east Asian countries. This finding
raises concern for development of
new candidate influenza  (H5N1) vac-
cine strains. Geographic spreading,
epidemiology, and genetic properties
of recently circulating influenza
(H5N1) viruses should be considered
when developing candidate H5N1
strains of influenza vaccine.
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Kala-azar Control,
Uganda
To the Editor: Much of the leish-
maniasis in Africa is concentrated in
East Africa. In this region, visceral
leishmaniasis (kala-azar) is caused by
Leishmania donovani and is endemic
in remote parts of Somalia, Sudan,
Ethiopia, Kenya, and Uganda (1).
In Uganda, kala-azar is transmit-
ted by the sandfly Phlebotomus marti-
ni, and transmission is thought to be
anthroponotic. Studies in Sudan and
Kenya have detected L. donovani in
domestic animals (2,3), but whether
these play a role in Uganda is
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unknown. In Uganda, the disease
appears to be restricted to Pokot
County, a semiarid lowland area in
Nakapiripirit District (see online map
in Appendix Figure, available at
www.cdc.gov/EID/content/13/3/507-
appG.htm). This focus is an extension
of a larger focus in West Pokot
District in Kenya (4). The area is
mainly inhabited by the Pokot, a
seminomadic tribe of pastoralists.
Nakapiripirit is one of the most under-
served districts of Uganda, plagued by
tribal clashes.
Though kala-azar has been report-
ed in East Africa since the early 1900s,
it was not described in Uganda until
the 1950s (5) and remained largely
unnoticed until 1997, when Médecins
Sans Frontières (MSF, Swiss Section)
began to provide assistance to Amudat
Health Centre in Pokot County. In
2000, MSF initiated a kala-azar con-
trol program, focusing on passive case
detection and treatment.
From January 2000 to February
2006, a total of 3,645 patients suspect-
ed of having kala-azar were screened
at Amudat Health Centre by using the
direct agglutination test or rK39 anti-
gen–based dipsticks (6); 2,088
patients with confirmed disease were
treated with daily intramuscular injec-
tions of sodium stibogluconate or
meglumine antimonite, 20 mg/kg
bodyweight, for 30 days. Overall,
80% of the patients were <15 years of
age, 75% were male, and 70% were
from Kenya. From 2000 through
2005, the number of patients treated
more than tripled, from 175 to 690
cases per year. Although this increase
likely results, at least in part, from
greater case detection due to the avail-
ability of treatment, we cannot
exclude a real increase in disease
because kala-azar prevalence in the
area is unknown.
Information on local vector
behavior and risk factors for infection
or disease (e.g., malnutrition and HIV
coinfection) is limited, and which
potential interventions are appropriate
is unclear. A pilot entomologic study
in 2004 (J. Stevenson, master’s thesis)
demonstrated that termite mounds
(Figure) are important vector breeding
and resting sites and that the practice
of sitting on termite mounds while
guarding livestock might increase the
risk for infection. In contrast, humans
may be protected from kala-azar when
in close proximity to livestock (i.e.,
because of diversion of sandflies to
alternative hosts) or when lighting
fires indoors (smoke acts as a repellant
to most biting flies). Ownership of
insecticide-treated nets, which could
protect persons from sandfly bites and
reduce kala-azar transmission (7), was
low. Although most of the local popu-
lation had heard of kala-azar, known
locally as termes, and regarded it as
potentially fatal, few were aware of
how kala-azar is transmitted (J.
Stevenson, master’s thesis).
MSF’s treatment of kala-azar is
crucial because it reduces the human
reservoir and hence transmission.
However, current control activities
only reach the tip of the iceberg: a
large, underlying pool of infected and
infectious persons likely exists (8,9).
Kala-azar in Uganda will not
likely be controlled unless the epi-
demiology of the disease is better
understood and preventive activities
are undertaken. This knowledge gap
is being addressed by a partnership
among the Malaria Consortium, MSF,
the London School of Hygiene and
Tropical Medicine, and the Vector
Control Division of the Ugandan
Ministry of Health. A case-control
study to determine the local risk fac-
tors of kala-azar is almost completed
and will be followed by seropreva-
lence studies in several Pokot vil-
lages, using a similar approach to
recent work in the Baringo District,
Kenya (9). The results will be used to
formulate an integrated control strate-
gy aimed at achieving our ultimate
goal of eliminating kala-azar from
Uganda.
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Figure. A large termite mound occupies the central area of this characteristic Pokot com-
pound. The mound provides a resting and breeding site for the sandly vector of visceral
leishmaniasis. Photographer: J.H. Kolaczinski.LETTERS
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Chikungunya Virus
Infection in
Traveler to
Australia
To the Editor: Chikungunya is a
mosquitoborne alphavirus in the fam-
ily  Togaviridae. Recently, a chikun-
gunya virus epidemic that affected
thousands of persons occurred in
islands in the southwestern Indian
Ocean, including Mauritius and
Reunion (1). An outbreak is ongoing
in India, and cases are being exported
to many other countries (2–4) The
likelihood of importation of exotic
infectious agents into Australia
increased during events such as the
March 2006 Commonwealth Games
in Melbourne. Urgent diagnosis of
rarely seen infections is a travel health
challenge, particularly when serologic
tests used for diagnosis in areas with
high prevalence are not locally avail-
able. Only 1 previously diagnosed
case of chikungunya virus infection
has been reported in Australia; it
involved importation of the virus
from Indonesia to Darwin in 1989 (5).
We report a second case of infection
with this virus.
A59-year-old man came to a hos-
pital emergency department in North
Melbourne, Australia, on March 12,
2006, 5 days after traveling from
Mauritius for the Commonwealth
Games. He reported a 2-day history of
acute swelling and erythema of the
left leg and associated malaise.
Twenty-four hours earlier, severe
lumbar back pain and arthralgias that
involved the lower limbs had devel-
oped, with associated fevers, rigors,
and headache.
The patient had a temperature of
39°C, bilateral conjunctivitis, tender
and markedly swollen Achilles ten-
dons, a swollen left ankle, and a mac-
ulopapular rash that involved the left
forefoot and anterior portion of the
shin. Initial blood examinations
showed leukopenia (leukocyte count
1.8 × 109/L, lymphocyte count 0.2 ×
109/L), mild thrombocytopenia
(platelet count 105 × 109/L), and
abnormal liver function test results
(alanine aminotransferase 133 IU/µL,
γ-glutamyl transpeptidase 141 IU/µL,
bilirubin 7 mmol/L). Malaria blood
films and dengue serologic results
were negative. A validated, in-house,
generic alphavirus reverse transcrip-
tion–PCR (RT-PCR) showed positive
results 24 hours after collection of
blood when the patient was admitted.
The patient received supportive
treatment and was discharged from
the hospital 3 days after admission, at
which time leukopenia and thrombo-
cytopenia had improved. The patient
had fully recovered on review 1 week
after discharge.
For virus isolation, plasma and
leukocyte fractions were placed onto
Vero E6 cells and incubated at 37°C
for 5 days. Cells were observed daily
for virus-specific cytopathic effects. A
virus isolate was obtained after 4 days
of cell culture. A 10-mL volume of
supernatant from infected cells was
applied to a carbon-coated grid,
stained with phototungstic acid, and
examined by electron microscopy.
This procedure showed virus with
morphology similar to Togavirus
(data not shown).
Chikungunya virus was identified
by a heminested RT-PCR for the non-